XNAS
MNOV
Market cap75mUSD
Oct 08, Last price
1.54USD
1D
-4.35%
1Q
10.79%
Jan 2017
-74.46%
IPO
-87.27%
Name
MediciNova Inc
Chart & performance
P/E
—
P/S
185.03
EPS
—
Div yield, %
—
Shrs. gr., 5y
2.01%
Rev. gr., 5y
%
Revenues
410k
Net income
-12m
L+8.58%
CFO
-10m
L-7.83%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. Its programs include MN-001, MN-166 neurology diseases, and MN-221 respiratory diseases. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.
Key people
Yuichi Iwaki
President, Chief Executive Officer, Director · since 2020
Jason Kruger
Chief Financial Officer · since 2022
David Crean
Chief Business Officer · since 2021
Kazuko Matsuda
Chief Medical Officer, Director · since 2019
Independent Director · since 2020
Hideki Nagao
Independent Director · since 2017
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||